文献速递心境障碍焦虑、强迫与应激相关障碍物质与行为成瘾

处方阿片类药物使用与重性抑郁及焦虑应激相关障碍风险:多变量孟德尔随机化分析

Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis.
PubMed 文献 · JAMA Psychiatry · 2021-01-01

该研究采用两样本孟德尔随机化方法,利用全基因组关联研究汇总数据,分析自报处方阿片类及非阿片类镇痛药使用与重性抑郁障碍(MDD)和焦虑应激相关障碍(ASRD)的潜在因果关联。

要点

  • 阿片类药物使用遗传易感性与MDD风险升高相关(OR 1.14)。
  • 阿片类药物使用遗传易感性与ASRD风险升高相关(多变量OR 1.30)。
  • MDD遗传易感性而非ASRD与阿片类药物使用风险升高双向相关。

核心结论

  • 孟德尔随机化分析提示阿片类药物使用遗传易感性与MDD和ASRD风险存在潜在因果关联。
  • 双向分析显示MDD遗传易感性而非ASRD与处方阿片类药物使用风险升高相关。

研究设计与样本

  • 采用两样本孟德尔随机化方法,利用全基因组关联研究汇总数据。
  • 数据来自 predominantly 欧洲 ancestry 的UK Biobank和Lundbeck Foundation Initiative for Integrative Psychiatric Research研究参与者。

主要发现

  • 单变量MR显示阿片类药物使用遗传易感性与MDD风险升高相关(OR 1.14,95%CI 1.06-1.22,P<.001)。
  • 单变量MR显示阿片类药物使用遗传易感性与ASRD风险升高相关(OR 1.24,95%CI 1.07-1.44,P=.004)。
  • 多变量MR调整其他非阿片类镇痛药后,MDD的OR为1.14(95%CI 1.04-1.25,P=.005),ASRD的OR为1.30(95%CI 1.08-1.46,P=.006)。
  • 双向分析显示MDD遗传易感性与阿片类药物使用风险升高相关(OR 1.18,95%CI 1.08-1.30,P<.001),ASRD无此关联。

关键数值与推荐

  • 主要结局为MDD和ASRD,暴露为自报处方阿片类及非阿片类镇痛药(NSAIDs、乙酰苯胺类、水杨酸类)使用。
  • 采用逆方差加权和多变量逆方差加权及MR-Egger敏感性分析,多效性稳健方法未提示多变量IVW估计存在偏倚。

临床怎么用

  • 结果提示处方阿片类药物使用可能增加MDD和ASRD风险,反之MDD遗传易感性也可能增加阿片类药物使用风险。
  • 临床中对于使用阿片类药物的患者应关注抑郁和焦虑症状的评估与监测。

局限性

  • 需要重复研究验证这些发现。
  • 研究基于 predominantly 欧洲 ancestry 人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Growing evidence suggests that prescription opioid use affects depression and anxiety disorders; however, observational studies are subject to confounding, making causal inference and determining the direction of these associations difficult. OBJECTIVE: To investigate the potential bidirectional associations between the genetic liability for prescription opioid and other nonopioid pain medications and both major depressive disorder (MDD) and anxiety and stress-related disorders (ASRD) using genetically based methods. DESIGN, SETTING, AND PARTICIPANTS: We performed 2-sample mendelian randomization (MR) using summary statistics from genome-wide association studies (GWAS) to assess potential associations of self-reported prescription opioid and nonopioid analgesics, including nonsteroidal anti-inflammatories (NSAIDs) and acetaminophen-like derivatives use with MDD and ASRD. The GWAS data were derived from participants of predominantly European ancestry included in observational cohorts. Data were analyzed February 20, 2020, to May 4, 2020. MAIN OUTCOMES AND MEASURES: Major depressive disorder, ASRD, and self-reported pain medications (opioids, NSAIDs, anilides, and salicylic acid). RESULTS: The GWAS data were derived from participants of predominantly European ancestry included in the population-based UK Biobank and Lundbeck Foundation Initiative for Integrative Psychiatric Research studies: approximately 54% of the initial UK Biobank sample and 55.6% of the Lundbeck Foundation Initiative for Integrative Psychiatric Research sample selected for the ASRD GWAS were women. In a combined sample size of 737 473 study participants, single-variable MR showed that genetic liability for increased prescription opioid use was associated with increased risk of both MDD (odds ratio [OR] per unit increase in log odds opioid use, 1.14; 95% CI, 1.06-1.22; P < .001) and ASRD (OR, 1.24; 95% CI, 1.07-1.44; P = .004). Using multivariable MR, these opioid use estimates remained after accounting for other nonopioid pain medications (MDD OR, 1.14; 95% CI, 1.04-1.25; P = .005; ASRD OR, 1.30; 95% CI, 1.08-1.46; P = .006), and in separate models, accounting for comorbid pain conditions. Bidirectional analyses showed that genetic liability for MDD but not ASRD was associated with increased prescription opioid use risk (OR, 1.18; 95% CI, 1.08-1.30; P < .001). These estimates were generally consistent across single-variable and multivariable inverse variance-weighted (MV-IVW) and MR-Egger sensitivity analyses. Pleiotropy-robust methods did not indicate bias in any MV-IVW estimates. CONCLUSIONS AND RELEVANCE: The findings of this mendelian randomization analysis suggest evidence for potential causal associations between the genetic liability for increased prescription opioid use and the risk for MDD and ASRD. While replication studies are necessary, these findings may inform prevention and intervention strategies directed toward the opioid epidemic and depression.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rosoff DB, Smith GD, Lohoff FW, et al. Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis. JAMA Psychiatry. 2021. PMID: 33175090. doi:10.1001/jamapsychiatry.2020.3554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。